ClinicalTrials.gg

Program

paliperidone

Also written as “Paliperidone ER”, “Paliperidone” and “Paliperidone palmitate”.

Its studies are mostly in Schizophrenia · Psychotic Disorders · Bipolar Disorder · Psychomotor Agitation, led by 4 companies.

Furthest: phase 4, since Aug 30, 2007106 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson1000 open or runningphase 4since Aug 30, 2007Nov 19, 2003none ahead
Luye Pharma Group30 open or runningphase 1since May 8, 2020May 8, 2020none ahead
CSPC Pharmaceutical Group21 open or runningno phasesince Sep 30, 2025Sep 30, 2025Dec 31, 2026NCT07493551
Pharmathen10 open or runningphase 2since Jan 26, 2018Jan 26, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 20, 2008.

  1. Apr 28, 2015Phase 3 study in SchizophreniaJohnson & Johnson · NCT02431702 · 337 enrolled · United States, Brazil, Mexico
  2. Jun 2, 2015Phase 2 study in SchizophreniaJohnson & Johnson · NCT02462473 · 9 enrolled · United States
  3. Nov 2, 2015Phase 1 study in ImmunoassayJohnson & Johnson · NCT02634463 · 81 enrolled · Belgium
  4. Mar 15, 2016Phase 3 study in SchizophreniaJohnson & Johnson · NCT02713282 · 306 enrolled · Croatia, Denmark, France and more
  5. Nov 14, 2017Phase 3 study in SchizophreniaJohnson & Johnson · NCT03345342 · 841 enrolled · United States, Argentina, Australia and more
  6. Jan 26, 2018Pharmathen's first study: phase 2 study in SchizophreniaNew to PharmathenPharmathen · NCT03425552 · 70 enrolled · Jordan
  7. Oct 18, 2018Phase 4 study in SchizophreniaJohnson & Johnson · NCT03713658 · 34 enrolled · Rwanda
  8. Aug 16, 2019Phase 3 study in SchizophreniaJohnson & Johnson · NCT04072575 · 178 enrolled · Argentina, Hong Kong, Italy and more
  9. May 8, 2020Luye Pharma Group's first study: phase 1 study in Schizophrenia PatientsNew to Luye Pharma GroupLuye Pharma Group · NCT04572685 · 36 enrolled · United States
  10. Apr 27, 2021Phase 1 study in SchizophreniaLuye Pharma Group · NCT04922593 · 281 enrolled · United States
  11. Jun 22, 2021Phase 4 study in SchizophreniaJohnson & Johnson · NCT04940039 · 93 enrolled · Rwanda
  12. Dec 6, 2021Phase 1 study in SchizophreniaLuye Pharma Group · NCT05321602 · 89 enrolled · United States
  13. Sep 30, 2025CSPC Pharmaceutical Group's first study: no phase study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07268430 · 256 enrolled · China
  14. Mar 4, 2026No phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07493551 · 260 planned · China

Ahead

  1. Dec 31, 2026Primary completion: no phase study in SchizophreniaCSPC Pharmaceutical Group · NCT07493551

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

The newest 60 of 106 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07493551Schizophrenia · China–RecruitingCSPC Pharmaceutical GroupDec 31, 2026260
NCT07268430Schizophrenia · China–CompletedCSPC Pharmaceutical GroupDec 25, 2024256
NCT05321602Schizophrenia · United States1CompletedLuye Pharma GroupSep 23, 202289
NCT04940039Schizophrenia · Rwanda4CompletedJohnson & JohnsonApr 16, 202493
NCT04922593Schizophrenia · United States1CompletedLuye Pharma GroupMar 15, 2022281
NCT04572685Schizophrenia Patients · United States1CompletedLuye Pharma GroupJun 26, 202036
NCT04072575Schizophrenia · Argentina, Hong Kong, Italy and more3CompletedJohnson & JohnsonMay 3, 2022178
NCT03713658Schizophrenia · Rwanda4CompletedJohnson & JohnsonDec 2, 201934
NCT03425552Schizophrenia · Jordan2CompletedPharmathenMay 2, 201970
NCT03345342Schizophrenia · United States, Argentina, Australia and more3CompletedJohnson & JohnsonMay 8, 2020841
NCT02713282Schizophrenia · Croatia, Denmark, France and more3CompletedJohnson & JohnsonMar 26, 2018306
NCT02634463Immunoassay · Belgium1CompletedJohnson & JohnsonNov 9, 201681
NCT02462473Schizophrenia · United States2TerminatedJohnson & JohnsonJan 20169
NCT02431702Schizophrenia · United States, Brazil, Mexico3CompletedJohnson & JohnsonNov 12, 2019337
NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more1CompletedJohnson & JohnsonOct 2014305
NCT01947803Schizophrenia · China4CompletedJohnson & JohnsonMar 2015353
NCT01942382Schizophrenia1CompletedJohnson & JohnsonMar 201076
NCT01724359Schizophrenia · Argentina, Colombia4CompletedJohnson & JohnsonNov 200995
NCT01685931Schizophrenia · China4CompletedJohnson & JohnsonDec 2014617
NCT01682161Schizophrenia · Korea, Republic of4CompletedJohnson & JohnsonSep 2013154
NCT01670071Schizophrenia · Taiwan4TerminatedJohnson & JohnsonJun 201517
NCT01662648Schizophrenia3CompletedJohnson & JohnsonApr 20081,117
NCT01607762Healthy · Belgium1CompletedJohnson & JohnsonApr 201231
NCT01606228Schizophrenia3CompletedJohnson & JohnsonDec 2008188
NCT01606254Schizophrenia · Japan2CompletedJohnson & JohnsonApr 200856
NCT01577186Schizophrenia4CompletedJohnson & JohnsonJun 2009480
NCT01577160Schizophrenia4CompletedJohnson & JohnsonApr 2009353
NCT01662310Schizophrenia · China3CompletedJohnson & JohnsonApr 2013201
NCT01561898Schizophrenia3CompletedJohnson & JohnsonOct 2008228
NCT01541371Schizophrenia3CompletedJohnson & JohnsonSep 2009405
NCT01529515Schizophrenia · United States, Colombia, Malaysia and more3CompletedJohnson & JohnsonApr 2014509
NCT01527305Schizophrenia · China, Korea, Republic of, Malaysia and more4CompletedJohnson & JohnsonDec 31, 2013212
NCT01515423Schizophrenia · United States, Argentina, Australia and more3CompletedJohnson & JohnsonFeb 20151,429
NCT01448720Schizophrenia · Brazil, Colombia, Mexico3CompletedJohnson & JohnsonDec 2013142
NCT01387542Schizophrenia · Thailand4CompletedJohnson & JohnsonSep 201040
NCT01362439Schizophrenia4CompletedJohnson & JohnsonMar 2010133
NCT01299389Schizophrenia · Japan, Korea, Republic of, Taiwan3CompletedJohnson & JohnsonMay 2012323
NCT01281527Schizophrenia · Austria, Belgium, Croatia and more3CompletedJohnson & JohnsonNov 20121,044
NCT01258920Schizophrenia · Japan3CompletedJohnson & JohnsonNov 2012201
NCT01193166Schizophrenia4WithdrawnJohnson & JohnsonSep 20120
NCT01193153Psychotic Disorders · United States, Bulgaria, India and more3CompletedJohnson & JohnsonOct 2013667
NCT01150448Schizophrenia · United States, Belgium, Croatia and more1CompletedJohnson & JohnsonJun 2009212
NCT01157351Schizophrenia · United States, Puerto Rico4CompletedJohnson & JohnsonDec 2013450
NCT01110317Schizophrenia1CompletedJohnson & Johnson49
NCT01081769Schizophrenia · Austria, Belgium, Bulgaria and more3CompletedJohnson & JohnsonFeb 2013769
NCT01094249Schizophrenia · United States1CompletedJohnson & JohnsonApr 20099
NCT01060228Schizophrenia1CompletedJohnson & Johnson24
NCT01050478Psychomotor Agitation · Belgium4CompletedJohnson & JohnsonDec 201156
NCT01051531Schizophrenia · Australia, China, Hong Kong and more3CompletedJohnson & JohnsonMay 17, 2013546
NCT01010776Schizophrenia · Brazil4CompletedJohnson & JohnsonDec 2009223
NCT01009047Schizophrenia · United States, India, Romania and more3CompletedJohnson & JohnsonJun 2012228
NCT00934635Schizophrenia · Germany4TerminatedJohnson & JohnsonDec 20092
NCT00946985Schizophrenia · United States, Brazil, Bulgaria and more4TerminatedJohnson & JohnsonMar 2010163
NCT00915512Schizophrenia · Turkey4CompletedJohnson & JohnsonOct 201184
NCT00892489Schizophrenia1CompletedJohnson & Johnson80
NCT00892541Schizophrenia1CompletedJohnson & Johnson30
NCT00892320Schizophrenia1CompletedJohnson & Johnson20
NCT00796835Schizophrenia1CompletedJohnson & Johnson50
NCT00796471Schizophrenia1CompletedJohnson & Johnson35
NCT00796185Schizophrenia1CompletedJohnson & Johnson62

How it is read

Names in the registry

  • “Paliperidone ER”, 39 entries
  • “Paliperidone”, 13 entries
  • “Paliperidone palmitate”, 10 entries
  • “paliperidone palmitate”, 7 entries
  • “Paliperidone Palmitate”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.